沙利度胺联合用药抗肿瘤研究进展

20世纪60年代沙利度胺因其具有致畸性而退出历史舞台，后来研究发现其致畸现象的背后是抗血管生成的作用。而抗血管生成作用这时已被学术界认为是对抗肿瘤生成的一个重要因素。后来，研究人员又发现了沙利度胺的其他抗肿瘤机制，这样沙利度胺便被作为一种极具潜力的抗肿瘤药物而被广泛研究。本文重点综述了沙利度胺的抗肿瘤作用机制以及它与其他药物联合用药用于治疗实体瘤的研究进展。

Research progress of thalidomide in combination therapy for the treatment of tumor

Following the reports of its teratogenici-ty, thalidomide was banned from the market in the 1960s. Later, researches discovered the teratogenicity was caused by inhibiting angiogenesis, and at that time the antiangiogenesis effect was considered an important factor in anti-tumour. Since then, many other anti-tumour mechanisms of thalidomide had been revealed and thalidomide was considered a kind of potential antitumor drug and was researched widely. This article focuses on the anti-tumour mechanisms of thalidomide and its use in combination therapy for the treatment of solid tumor.